1 Fusionopolis Way
#20-10 Connexis North Tower
316 articles with A*STAR
Former Top A*STAR Scientists Launch Abasia, A Singapore-based Reagents Manufacturer, To Support Increased Testing Locally
Reagents are critical raw materials in COVID-19 diagnostic kits. Local production secures Singapore’s goal to make testing part of the new normal, and mitigate disruptions from the international supply chain
Advanced Medtech Commercialises Industry-first SARS-CoV-2 Direct Multiplex RT-PCR Assay Co-developed By A*STAR and DSO
RESOLUTE 2.0, an industry-first SARS-CoV-2 direct multiplex Reverse-Transcription Polymerase-Chain-Reaction assay kit co-developed by Singapore’s Agency for Science Technology and Research and DSO National Laboratories, has been made available for clinical use in Singapore by Advanced MedTech Holdings, a global medical technology leader.
Lucence, A*STAR Share Study Data Showing SAFER™ Sample Saliva Collection Kit for COVID-19 Inactivates Collected Virus
SAFER™ Sample Kit offers accessible, non-invasive, and safe sample collection via saliva to enable cost-effective mass testing;
TurtleTree Labs sets to showcase the world's first human breast milk using cell-based technology at their April 21, 2020 Future of Clean Milk launch.
A single AQP5+ human gastric stem cell gives rise to a 3D gastric organoid that re-expresses AQP5.
Study showed that two metabolic enzymes in the proline metabolic pathway are potential targets to inhibit cancer cell growth, and offers new hope for effective liver cancer treatments
A!maginostic Partners A*STAR’s Institute Of Molecular And Cell Biology To Establish A New Joint Lab Of Excellence For Smart Digital And Multiplex Pathology
The collaboration will use Image Processing and Artificial Intelligence/Machine Learning to revolutionise pathology practice and provide more precise cancer diagnostic assays
A scientific study of African populations discovers that the beta-amyloid gene is associated with an increased risk of the most common form of glaucoma
A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.
Two teams and an individual have been awarded this year’s President’s Science and Technology Awards, the highest honours bestowed upon research scientists and engineers in Singapore whose work have resulted in significant scientific, technological or economic benefits for the country.
Studies on a novel protein that helps cancer cells to grow and spread may help in the development of more efficient therapies for liver cancer
Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have developed a customisable hydrogel that cultivates patient-derived tumour organoids which can better mimic the original.
Researchers from Singapore and the United States are focused on a novel drug candidate with marine origins as a new method to prevent or treat vision loss.
Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have successfully developed an innovative nanocarrier derived from green tea catechins, which can deliver anti-cancer drugs in a targeted and effective fashion.
Singapore scientists and clinicians have discovered a promising use of antibodies to target a new cancer antigen, as an alternative for chemotherapy
A new high-resolution approach using portable DNA sequencers provides a more complete genomic picture of antibiotic resistance in gut bacteria
MIT's research enterprise in Singapore launches new research group, boosting nation's cell therapies R&D
MIT's Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore's National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
The nation’s drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development.
Scientists from the Agency for Science, Technology and Research’s Genome Institute of Singapore have identified two new Epstein-Barr Virus viral variants associated with cancers, including nasopharyngeal carcinoma, gastric cancer, and several kinds of lymphomas.